PD-L1 IHC Blueprint Project: Ongoing Progress Toward Consistency Among Assays
By Fred R. Hirsch, MD, PhD
Posted: April 2018
Immunotherapy is a very encouraging development in the treatment of patients with lung cancer. At this phase of...
AACR 2018: First-Line Management of Advanced NSCLC Enters New Era
By Corey Langer, MD, IASLC Lung Cancer News Editor
Posted: June 2018
The therapeutic landscape irrevocably altered on April 17, 2018, when three pivotal trials—KEYNOTE 189,...
Timing of Immune Checkpoint Inhibitors With Respect to Molecular Testing in NSCLC
By Maria Antonia Velez, MD; Nanruoyi Zhou, BA; Brian Henick, MD; and Aaron Lisberg, MD
Posted: August 19, 2020
Immune checkpoint inhibitors (CPIs) have revolutionized the...
KEYNOTE-042: No Hard and Fast Rules for First-Line Pembrolizumab Regarding PD-L1–Positive Disease
By Kara Nyberg, PhD
Posted: August 2018
The pace of research focused on new therapies for advanced NSCLC has progressed from a trot to a sprint...
Explaining IMpower132: An Interview with Dr. Vassiliki A. Papadimitrakopoulou
Posted: December 2018
In the following interview, Vassiliki A. Papadimitrakopoulou, MD, Jay and Lori Eisenberg Distinguished Professor of Medicine and section chief of Thoracic Medical...
Immunotherapy Adverse-Event Treatment Resource Guide
The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...
Targeted Therapy Plus Immune Checkpoint Inhibitors: Research Opportunities, But No Improvement in Activity to...
By Ross Soo, MB BS, PhD, FRACP
Posted: December 2018
The treatment of patients with advanced NSCLC harbouring an actionable oncogene with tyrosine kinase inhibitors (TKIs)...
Management of Immunotherapy Toxicity in NSCLC
By Beth Eaby-Sandy, MSN, CRNP
Posted: February 2018
When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was...
Neoadjuvant Nivolumab Shows Unprecedented Pathologic Complete Response for Stage III NSCLC
By Mariano Provencio-Pulla, MD, PhD
Posted: December 2018
Patients with stage IIIA NSCLC with clinically evident N2 nodal spread have an overall 5-year survival rate of...
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO
Posted: February 2018
The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For...
